Founded in 2004, Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry. The company has invested in its people and facilities and established its comprehensive service offerings throughout the pharmaceutical R&D lifecycle. With operations in China, the US and the UK staffed by more than 11,000 employees, Pharmaron has an excellent track record in delivering end-to-end R&D solutions to its partners globally and enabling them to accelerate their novel drug discovery and development process.
Pharmaron is a contract research organization (CRO).
* Synthetic, medicinal and analytical chemistry services
* Biology services
* DMPK services
* Pharmacology services
* Drug safety assessment services
* Radiochemistry and isotopically labelled metabolism services
* Chemical & pharmaceutical development services
* Clinical development services
CRO - Contract Research Organization
Discovery Process Chemistry
Radiolabelled Chemical Synthesis
in vitro Biology
in vitro Screening
in vivo Pharmacology
Animal Disease Models
ex vivo Pharmacology
in vitro ADME
in vivo PK
Drug Product Manufacturing
14C / Carbon-14 Radiosynthesis
3H / Tritium Radiosynthesis
Microdosing Phase 0
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated contract research, development and manufacturing organization providing scientific services – from early discovery to commercial supply. Our innovative capabilities for novel molecular entities (NMEs) cater to a wide range of industrial sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods and speciality chemical companies.
Our Discovery services include conducting early-stage research from target identification to delivery of drug candidates for further development. Development services encompass activities from pre-clinical to clinical trials including Drug Substance Development (DSP), Drug Product Development (DPD) and associated services to demonstrate safety, tolerability and efficacy of the selected drug candidate.
Our Manufacturing services for small and large molecules include cGMP-compliant facilities for clinical supplies, registration batches as well as commercial volumes through our API manufacturing plant & disposable Biologics manufacturing facility.
Driving our innovative culture is our highly qualified team of 4200 scientists supported by state-of-the-art infrastructure and market-leading technology. Our scientists have both the skills and the capability to deliver great science, ensure robust data management, IP security & quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation.
With 2 Mn sq ft of specialist discovery, development & manufacturing facilities, Syngene offers dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife. We also work with biotech companies pursuing leading-edge science as well as multinationals including GSK and Merck KGaA. Smaller and virtual companies, non-profit institutions, academic centers and start-ups also collaborate with us for their research-related requirements.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."
AcceGen Biotech proudly develops innovative technologies for the pharmaceutical, biotech and specialty ingredients markets. We are committed to supplying the best products and services with global manufacturing, development expertise and advanced technologies to enhance the overall quality of life.
AcceGen Biotech developed significant expertise in cell and genomic research. We provide a variety of high-quality human/animal cells, cell media/kits, cell-derived molecular biology products, gene-based assay kits, Clones, Fish probes and Sequencing products for research use.
AcceGen Biotech offers custom cell line generation, microRNA sponges and microRNA Agomir/Antagomir services to simplify the gene research. The aim is to accelerate scientific discovery related to genetic analysis available to academic researchers as well as commercial enterprises.
AcceGen Biotech has permanent facilities in Fairfield (New Jersey). We take care of our customers and their global, regional or local requirements. We welcome potential partners and distributors to explore our business all over the world.
Accelrys was founded in 2001 from the combination of five companies: Molecular Simulations Inc, Synopsys Scientific Systems, Oxford Molecular, the Genetics Computer Group (GCG), and Synomics Ltd. In 2004, Accelrys acquired SciTegic, the developer of Pipeline Pilot data pipelining and scientific workflow authoring software.
In July 2010, Accelrys merged with Symyx Technologies, Inc., combining the Accelrys portfolio of scientific informatics solutions with the market-leading Symyx electronic laboratory notebook (ELN). The Accelrys-Symyx merger also extended Accelrys’ product offerings with certain software and content products from MDL Information Systems, Inc., which Symyx had acquired from Elsevier, Inc. in 2007. MDL had been a premier scientific software vendor for over 25 years with critical software solutions deployed across approximately 750 organizations.
Subsequently, Accelrys further extended its scientific informatics and product lifecycle management capabilities through the acquisitions of:
• Contur Software
• VelQuest Corp
• Aegis Analytical Corp
• Vialis AG
• ChemSW, Inc.
Accelrys’ deliberate merger and acquisition strategy made the company one of the largest, most comprehensive scientific informatics companies in the world with a clear focus on creating, driving and delivering wide-ranging scientific product lifecycle management solutions across the research, development, QA/QC and manufacturing phases of product development.
After acquiring Accelrys on April 29, 2014, Dassault Systèmes announced the creation of BIOVIA on May 21, 2014, describing the new company as a combination of Accelrys’ leading life sciences and materials sciences solutions with Dassault Systèmes activities in BioIntelligence and its collaborative 3DEXPERIENCE® platform.